-
If you haven't included expedited partner therapy (EPT) in your practice of treating patients with gonorrhea and chlamydia, more support for the measure has arrived in the form of a new committee opinion from the American College of Obstetricians and Gynecologists.
-
Results from a new survey by the Centers for Disease Control and Prevention (CDC) show that teen vaccination rates for human papillomavirus (HPV) remain low in comparison with other vaccines administered to young adults.
-
Results from an analysis presented at the recent 2011 International AIDS Society conference in Rome suggest that using certain methods of hormonal contraception particularly injectable contraception might double the risk of HIV acquisition in a previously uninfected woman and also might double the risk that an HIV- infected woman will transmit HIV to a previously uninfected male sexual partner.
-
In a commentary on preterm birth (PTB) in the april issue of OB/GYN Clinical Alert, I mentioned that data are on the horizon that would support the use of vaginal progesterone to reduce the risk of PTB in patients with short cervices. Well, the study has now been published, and the results may change how PTB is approached.
-
In this issue: Medication poisonings in children; rosuvastatin vs atorvastatin for atherosclerosis; saw palmetto for prostate symptoms; using atypical antipsychotics for off-label indications in adults; and FDA actions.
-
The authors performed a retrospective cohort study to evaluate the clinical utility of dilation and curettage (D&C) in diagnosing ectopic pregnancy (EP).
-
Thyroid dysfunction and disease may present as reproductive compromise including oligomenorrhea, infertility, and miscarriage. Thyroid dysfunction and disease may complicate pregnancy and lead to compromised fetal neurodevelopment and preterm labor.
-
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is commonly mutated in endometrial and other cancers.
-
-
In this double-blind protocol, normal-weight (body mass index [BMI] 19.0-24.9 kg/m2) and obese (BMI 30.0-39.9 kg/m2) women with regular periods and normal ovarian ultrasound took one of two types of oral contraceptives (OCPs): either 21-day monophasic pills with 20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel.